'''Bromantane''', sold under the brand name '''Ladasten''', is an atypical [[psychostimulant]] and [[anxiolytic]] [[drug]] of the [[adamantane]] family related to [[amantadine]] and [[memantine]] which is used in Russia in the treatment of [[neurasthenia]]. Although the effects of the bromantane have been determined to be dependent on the [[dopaminergic]] and possibly [[serotonergic]] [[neurotransmitter]] systems, its exact [[mechanism of action]] is unknown,<ref name="GrekhovaGainetdinov1995">{{cite journal|last1=Grekhova|first1=T. V.|last2=Gainetdinov|first2=R. R.|last3=Sotnikova|first3=T. D.|last4=Krasnykh|first4=L. M.|last5=Kudrin|first5=V. S.|last6=Sergeeva|first6=S. A.|last7=Morozov|first7=I. S.|title=Effect of bromantane, a new immunostimulating agent with psychostimulating activity, on the release and metabolism of dopamine in the striatum of freely moving rats. A microdialysis study|journal=Bulletin of Experimental Biology and Medicine|volume=119|issue=3|year=1995|pages=294–296|issn=0007-4888|doi=10.1007/BF02445840}}</ref><ref name="IezhitsaSpasov2001">{{cite journal|last1=Iezhitsa|first1=Igor N.|last2=Spasov|first2=Alexander A.|last3=Bugaeva|first3=Lubov I.|title=Effects of bromantan on offspring maturation and development of reflexes|journal=Neurotoxicology and Teratology|volume=23|issue=2|year=2001|pages=213–222|issn=0892-0362|doi=10.1016/S0892-0362(01)00119-2|pmid=11348840}}</ref> and it is distinct in its properties relative to typical psychostimulants such as [[amphetamine]]. Because of its unique aspects, bromantane has sometimes been described instead as an [[adaptogen]] and [[actoprotector]].<ref name="SpasovKhamidova2000">{{cite journal|last1=Spasov|first1=A. A.|last2=Khamidova|first2=T. V.|last3=Bugaeva|first3=L. I.|last4=Morozov|first4=I. S.|title=Adamantane derivatives: Pharmacological and toxicological properties (review)|journal=Pharmaceutical Chemistry Journal|volume=34|issue=1|year=2000|pages=1–7|issn=0091-150X|doi=10.1007/BF02524549}}</ref><ref name="MorozovIvanova2001">{{cite journal|last1=Morozov|first1=I. S.|last2=Ivanova|first2=I. A.|last3=Lukicheva|first3=T. A.|title=Actoprotector and Adaptogen Properties of Adamantane Derivatives (A Review)|journal=Pharmaceutical Chemistry Journal|volume=35|issue=5|year=2001|pages=235–238|issn=0091-150X|doi=10.1023/A:1011905302667}}</ref>

 
The therapeutic effects of bromantane in asthenia are said to onset within 1- to 3-days.<ref name="pmid21322821" /> It has been proposed that the combination of psychostimulant and anxiolytic activity may give bromantane special efficacy in the treatment of asthenia.<ref name="pmid19491814" />

 
In a large-scale, multi-center [[clinical trial]] of 728 patients diagnosed with asthenia, bromantane was given for 28 days at a daily dose of 50&nbsp;mg or 100&nbsp;mg.<ref name="pmid21322821" /> The impressiveness were 76.0% on the [[Clinical Global Impression|CGI-S]] and 90.8% on the [[Clinical Global Impression|CGI-I]], indicating broadly-applicable, high effectiveness.<ref name="pmid21322821" /> The therapeutic benefit against asthenia was notably observed to still be present one-month after discontinuation of the drug, indicating long-lasting positive effects of bromantane.<ref name="pmid21322821" /> [[Quality of life]] was significantly increased by bromantane, and this increase remained at one-month after withdrawal of bromantane.<ref name="pmid21322821" /> 3% of patients experienced side effects; none of the adverse effects were serious; and 0.8% of patients discontinued treatment due to side effects.<ref name="pmid21322821" /> Bromantane was also noted to normalize the [[sleep-wake cycle]].<ref name="pmid21322821" /> The authors concluded that "[Bromantane] in daily dose from 50 to 100 mg is a highly effective, well-tolerated and [safe] drug with a wide spectrum of clinical effects. Therefore, this drug could be recommended for treatment of asthenic disorders in neurological practice."<ref name="pmid21322821" />

 
===Effects and benefits===

 
Bromantane is described primarily as a mild psychostimulant<ref name="MikhaylovaVakhitova2007">{{cite journal|last1=Mikhaylova|first1=M|last2=Vakhitova|first2=J|last3=Yamidanov|first3=R|last4=Salimgareeva|first4=M|last5=Seredenin|first5=S|last6=Behnisch|first6=T|title=The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats|journal=Neuropharmacology|volume=53|issue=5|year=2007|pages=601–608|issn=0028-3908|doi=10.1016/j.neuropharm.2007.07.001|pmid=17854844}}</ref> and anxiolytic.<ref name="pmid19491814" /> It is also said to possess [[antiasthenic]] properties.<ref name="OliynykOh2012" /><ref name="pmid19491814" /> Bromantane is reported to improve physical and mental performance, and hence could be considered a [[performance-enhancing drug]].<ref name="OliynykOh2012" />

 
Bromantane has been found to lower the levels of [[pro-inflammatory cytokine]]s [[Interleukin 6|IL-6]], [[Interleukin 17|IL-17]] and [[Interleukin 4|IL-4]] and to normalize behavior in animal models of [[depression (mood)|depression]], and may possess clinical efficacy as an [[antidepressant]].<ref name="pmid22288152">{{cite journal | vauthors = Tallerova AV, Kovalenko LP, Durnev AD, Seredenin SB | title = [Effect of antiasthenic drug ladasten on the level of cytokines and behavior in experimental model of anxious depression in C57BL/6 male mice] | language = Russian | journal = Eksp Klin Farmakol | volume = 74 | issue = 11 | pages = 3–5 | year = 2011 | pmid = 22288152 | doi = | url = }}</ref><ref name="TallerovaKovalenko2011">{{cite journal|last1=Tallerova|first1=A. V.|last2=Kovalenko|first2=L. P.|last3=Durnev|first3=A. D.|last4=Seredenin|first4=S. B.|title=Effect of Ladasten on the Content of Cytokine Markers of Inflammation and Behavior of Mice with Experimental Depression-Like Syndrome|journal=Bulletin of Experimental Biology and Medicine|volume=152|issue=1|year=2011|pages=58–60|issn=0007-4888|doi=10.1007/s10517-011-1453-2}}</ref><ref name="TallerovaKovalenko2014b">{{cite journal|last1=Tallerova|first1=A. V.|last2=Kovalenko|first2=L. P.|last3=Kuznetsova|first3=O. S.|last4=Durnev|first4=A. D.|last5=Seredenin|first5=S. B.|title=Correcting Effect of Ladasten on Variations in the Subpopulation Composition of T Lymphocytes in C57Bl/6 Mice on the Experimental Model of an Anxious-Depressive State|journal=Bulletin of Experimental Biology and Medicine|volume=156|issue=3|year=2014|pages=335–337|issn=0007-4888|doi=10.1007/s10517-014-2343-1}}</ref> It has also been found to increase sexual receptivity and proceptivity in rats of both sexes, which was attributed to its dopaminergic actions.<ref name="pmid15341065">{{cite journal | vauthors = Kuzubova EA, Bugaeva LI, Spasov AA | title = [The effect of bromantan on the sexual behavior and conception in rats] | language = Russian | journal = Eksp Klin Farmakol | volume = 67 | issue = 3 | pages = 34–7 | year = 2004 | pmid = 15341065 | doi = | url = }}</ref> It has been proposed that bromantane may suppress [[prolactin]] levels by virtue of its dopaminergic properties as well.<ref name="pmid10650526">{{cite journal | vauthors = Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS | title = [The effect of the actoprotector preparation bromantane on the postnatal development of rat pups] | language = Russian | journal = Eksp Klin Farmakol | volume = 62 | issue = 6 | pages = 39–44 | year = 1999 | pmid = 10650526 | doi = | url = }}</ref> Bromantane has been found to "agonize" amphetamine-induced stereotypies ''in vivo'', suggesting that it might potentiate certain effects of other psychostimulants.<ref name="IezhitsaSpasov2001" />

 
Although it is frequently labeled as a psychostimulant, bromantane is distinct in its [[pharmacology]] and effects relative to typical psychostimulants, such as the [[substituted phenethylamine|phenethylamine]]s (e.g., [[amphetamine]] and its derivatives) and their [[structural analog]]ues (e.g., [[methylphenidate]], [[cocaine]], [[mesocarb]], etc.).<ref name="pmid11348840">{{cite journal | vauthors = Iezhitsa IN, Spasov AA, Bugaeva LI | title = Effects of bromantan on offspring maturation and development of reflexes | journal = Neurotoxicol Teratol | volume = 23 | issue = 2 | pages = 213–22 | year = 2001 | pmid = 11348840 | doi = 10.1016/s0892-0362(01)00119-2| url = }}</ref><ref name="VakhitovaYamidanov2005a">{{cite journal|last1=Vakhitova|first1=Yu. V.|last2=Yamidanov|first2=R. S.|last3=Vakhitov|first3=V. A.|last4=Seredenin|first4=S. B.|title=cDNA macroarray analysis of gene expression changes in rat brain after a single administration of a 2-aminoadamantane derivative|journal=Molecular Biology|volume=39|issue=2|year=2005|pages=244–252|issn=0026-8933|doi=10.1007/s11008-005-0035-7}}</ref> Whereas the latter directly act on the [[dopamine transporter]] to [[reuptake inhibitor|inhibit]] the [[reuptake]] and/or [[releasing agent|induce]] the [[neurotransmitter release|release]] of dopamine, bromantane instead acts via indirect [[genomic]] mechanisms to produce a rapid, pronounced, and long-lasting [[downregulation and upregulation|upregulation]] in a variety of brain regions of the [[gene expression|expression]] of [[tyrosine hydroxylase]] (TH) and [[aromatic L-amino acid decarboxylase|aromatic <small>L</small>-amino acid decarboxylase]] (AAAD) (also known as DOPA decarboxylase), key [[enzyme]]s in the dopamine [[biosynthesis]] pathway.<ref name="MikhaylovaVakhitova2007" /><ref name="pmid15500036">{{cite journal | vauthors = ((Vakhitova IuV)), Iamidanov RS, Seredinin SB | title = [Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain] | language = Russian | journal = Eksp Klin Farmakol | volume = 67 | issue = 4 | pages = 7–11 | year = 2004 | pmid = 15500036 | doi = | url = }}</ref><ref name="VakhitovaYamidanov2005b">{{cite journal|last1=Vakhitova|first1=Yu. V.|last2=Yamidanov|first2=R. S.|last3=Vakhitov|first3=V. A.|last4=Seredenin|first4=S. B.|title=The effect of ladasten on gene expression in the rat brain|journal=Doklady Biochemistry and Biophysics|volume=401|issue=1–6|year=2005|pages=150–153|issn=1607-6729|doi=10.1007/s10628-005-0057-z}}</ref> For instance, a single dose of bromantane produces a 2- to 2.5-fold increase in TH expression in the rat [[hypothalamus]] 1.5- to 2-hours post-administration.<ref name="pmid16915929">{{cite journal | vauthors = ((Vakhitova IuV)), Sadovnikov SV, Iamidanov RS, Seredenin SB | title = [Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten] | language = Russian | journal = Genetika | volume = 42 | issue = 7 | pages = 968–75 | year = 2006 | pmid = 16915929 | doi = | url = }}</ref> The biosynthesis and release of dopamine subsequently increase in close correlation with TH and AAAD upregulation.<ref name="MikhaylovaVakhitova2007" /><ref name="pmid15500036" /><ref name="VakhitovaYamidanov2005b" /> Enhancement of dopaminergic [[neurotransmission]] is observed in the hypothalamus, [[striatum]], [[ventral tegmental area]], [[nucleus accumbens]], and other regions.<ref name="MikhaylovaVakhitova2007" /><ref name="pmid15500036" /><ref name="VakhitovaYamidanov2005b" /> As such, the key mechanism of the pharmacological activity and psychostimulant effects of bromantane is activation of the ''de novo'' synthesis of dopamine via modulation of gene expression.<ref name="pmid15500036" /> In contrast, typical psychostimulants do not affect TH or AAAD expression and thus have no effect on dopamine biosynthesis.<ref name="VakhitovaYamidanov2005a" /><ref name="pmid20369592">{{cite journal | vauthors = Zimin IA, Abaimov DA, Budygin EA, ((Zolotarev IuA)), Kovalev GI | title = [Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb] | language = Russian | journal = Eksp Klin Farmakol | volume = 73 | issue = 2 | pages = 2–5 | year = 2010 | pmid = 20369592 | doi = | url = }}</ref>

 
* "Bromantane administration in therapeutic doses is characterized by the almost full absence of side effects including manifestations of withdrawal syndrome and hyperstimulation."

 
* "[Bromantane] has low peripheral sympathomimetic effects. Moreover, no signs of [bromantane] dependence and withdrawal symptoms were found."

 
As such, bromantane has few to no [[side effect]]s (including peripheral sympathomimetic effects and hyperstimulation), does not seem to produce [[drug tolerance|tolerance]] or [[drug dependence|dependence]], does not show [[drug withdrawal|withdrawal]] symptoms upon discontinuation, and displays an absence of [[addiction potential]], all of which are quite contrary to typical psychostimulants.<ref name="OliynykOh2012" /><ref name="pmid19491814" /> In accordance with human findings, animals exposed to bromantane for extended periods of time do not appear to develop tolerance or dependence either.<ref name="pmid11109517">{{cite journal | vauthors = Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS | title = [Effect of bromantane on the rat neurologic status in two month course] | language = Russian | journal = Eksp Klin Farmakol | volume = 63 | issue = 5 | pages = 13–7 | year = 2000 | pmid = 11109517 | doi = | url = }}</ref>

 
The precise direct molecular [[mechanism of action]] by which bromantane ultimately acts as a dopamine synthesis enhancer is unknown.<ref name="GrekhovaGainetdinov1995" /><ref name="IezhitsaSpasov2001" /> However, it has been determined that activation of certain [[cAMP-dependent pathway|cAMP-]], [[calcium|Ca<sup>2+</sup>-]], and [[phospholipid]]-dependent [[protein kinase]]s such as [[protein kinase A]] and especially [[protein kinase C]] corresponds with the manifestation of the pharmacological effects of bromantane.<ref name="VakhitovaYamidanov2005a" /><ref name="pmid15188752">{{cite journal | vauthors = ((Vakhitova IuV)), ((Salimgareeva MKh)), Seredenin SB | title = [Effect of ladasten on the proteinase C activity in the rat brain cells] | language = Russian | journal = Eksp Klin Farmakol | volume = 67 | issue = 2 | pages = 12–5 | year = 2004 | pmid = 15188752 | doi = | url = }}</ref> As such, bromantane seems to be activating intracellular signaling cascades by some mechanism (e.g., [[agonist|agonizing]] some as-yet-undetermined [[receptor (biochemistry)|receptor]]) to in turn activate protein kinases, which in turn cause increased [[gene transcription|transcription]] of TH and AAAD.<ref name="VakhitovaYamidanov2005a" /><ref name="pmid15188752" />

 
In 2004, it was discovered that amantadine and [[memantine]] bind to and act as [[agonist]]s of the [[sigma-1 receptor|σ<sub>1</sub> receptor]] (K<sub>i</sub> = 7.44 µM and 2.60 µM, respectively), and that activation of the σ<sub>1</sub> receptor is involved in the central dopaminergic effects of amantadine at therapeutically relevant concentrations.<ref name="PeetersRomieu2004">{{cite journal|last1=Peeters|first1=Magali|last2=Romieu|first2=Pascal|last3=Maurice|first3=Tangui|last4=Su|first4=Tsung-Ping|last5=Maloteaux|first5=Jean-Marie|last6=Hermans|first6=Emmanuel|title=Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine|journal=European Journal of Neuroscience|volume=19|issue=8|year=2004|pages=2212–2220|issn=0953-816X|doi=10.1111/j.0953-816X.2004.03297.x|pmid=15090047}}</ref> These findings may also extend to the other adamantanes such as adapromine, rimantadine, and bromantane, and might potentially explain the psychostimulant-like effects of this family of compounds, possibly including those of bromantane.<ref name="PeetersRomieu2004" />

 
Bromantane was once thought to act as a reuptake inhibitor of serotonin and dopamine.<ref name="GrekhovaGainetdinov1995"/><ref name="pmid11348840" /><ref name="pmid10198757">{{cite journal | vauthors = Morozov IS, Pukhova GS, Avdulov NA, Sergeeva SA, Spasov AA, Iezhitsa IN | title = [The mechanisms of the neurotropic action of bromantan] | language = Russian | journal = Eksp Klin Farmakol | volume = 62 | issue = 1 | pages = 11–4 | year = 1999 | pmid = 10198757 | doi = | url = }}</ref> Indeed, bromantane does inhibit the reuptake of serotonin, dopamine, and to a lesser extent [[norepinephrine]] ''in vitro'' in rat brain tissue.<ref name="pmid11348840" /><ref name="pmid10198757" /> However, the concentrations required to do so are extremely high (50–500 µM) and likely not clinically relevant.<ref name="pmid11348840" /><ref name="pmid10198757" /> (Although one study found an [[IC50|IC<sub>50</sub>]] for dopamine transport of 3.56 µM, relative to 28.66 nM for mesocarb; neither drug affected serotonin transport at the tested concentrations, in contrast.)<ref name="pmid20369592" /> In any case, the lack of typical psychostimulant-like effects and adverse effects seen with bromantane supports the notion that it is not acting significantly as a [[monoamine reuptake inhibitor]], but rather via enhancement of dopamine synthesis.

 
Although not relevant at clinical dosages, bromantane has been found to produce [[anticholinergic]] effects, including both [[antimuscarinic]] and [[antinicotinic]] actions, at very high doses in animals, and these effects are responsible for its [[toxicity]] (that is, [[LD50|LD<sub>50</sub>]]) in animals.<ref name="pmid10198757"/><ref name="pmid10763112">{{cite journal | vauthors = Bugaeva LI, Verovskiĭ VE, Iezhitsa IN, Spasov AA | title = [An acute toxicity study of bromantane] | language = Russian | journal = Eksp Klin Farmakol | volume = 63 | issue = 1 | pages = 57–61 | year = 2000 | pmid = 10763112 | doi = | url = }}</ref><ref>{{cite journal | pmid = 12124651 | year = 2002 | last1 = Iezhitsa | first1 = IN | last2 = Spasov | first2 = AA | last3 = Bugaeva | first3 = LI | last4 = Morozov | first4 = IS | title = Toxic effect of single treatment with bromantane on neurological status of experimental animals | volume = 133 | issue = 4 | pages = 380–3 | journal = Bulletin of experimental biology and medicine}}</ref><ref name="IezhitsaSpasov2002">{{cite journal|last1=Iezhitsa|first1=I. N.|last2=Spasov|first2=A. A.|last3=Bugaeva|first3=L. I.|last4=Morozov|first4=I. S.|title=Toxic Effect of Single Treatment with Bromantane on Neurological Status of Experimental Animals|journal=Bulletin of Experimental Biology and Medicine|volume=133|issue=4|year=2002|pages=380–383|issn=0007-4888|doi=10.1023/A:1016206306875}}</ref>

 
The psychostimulant effects of bromantane onset gradually within 1.5- to 2-hours and last for 8- to 12-hours.<ref name="MikhaylovaVakhitova2007" />

 
In the 1960s, the adamantane derivative [[amantadine]] (1-aminoadamantane) was developed as an [[antiviral drug]] for the treatment of [[influenza]].<ref name="MandellWoodhead2006">{{cite book|author1=Lionel Mandell|author2=Mark Woodhead|author3=Santiago Ewig|author4=Antoni Torres|title=Respiratory Infections|url=https://books.google.com/books?id=qif7D7v2QgUC&pg=PA243|date=27 October 2006|publisher=CRC Press|isbn=978-0-340-81694-3|pages=243–}}</ref> Other adamantane antivirals subsequently followed, such as [[rimantadine]] (1-(1-aminoethyl)adamantane) and [[adapromine]] (1-(1-aminopropyl)adamantane).<ref name="SpasovKhamidova2000"/><ref name="MandellWoodhead2006" /> It was serendipitously discovered in 1969 that amantadine possesses central [[dopaminergic]] psychostimulant-like properties,<ref name="Brandt2003">{{cite book|author=Thomas Brandt|title=Neurological Disorders: Course and Treatment|url=https://books.google.com/books?id=q9h5Xg3pwAYC&pg=PA1047|year=2003|publisher=Gulf Professional Publishing|isbn=978-0-12-125831-3|pages=1047–}}</ref><ref name="PackerSies2009">{{cite book|author1=Lester Packer|author2=Helmut Sies|author3=Manfred Eggersdorfer|author4=Enrique Cadenas|title=Micronutrients and Brain Health|url=https://books.google.com/books?id=ylX-GBKyLLkC&pg=PA71|date=6 October 2009|publisher=CRC Press|isbn=978-1-4200-7352-2|pages=71–}}</ref> and subsequent investigation revealed that rimantadine and adapromine also possess such properties.<ref name="KrapivinSergeeva1998">{{cite journal|last1=Krapivin|first1=S. V.|last2=Sergeeva|first2=S. A.|last3=Morozov|first3=I. S.|title=Comparative analysis of the effects of adapromine, midantane, and bromantane on bioelectrical activity of rat brain|journal=Bulletin of Experimental Biology and Medicine|volume=125|issue=2|year=1998|pages=151–155|issn=0007-4888|doi=10.1007/BF02496845}}</ref> Amantadine was then developed and introduced for the treatment of [[Parkinson's disease]] due to its ability to increase [[dopamine]] levels in the brain.<ref name="Brandt2003" /> It has also notably since been used to help alleviate [[fatigue (medical)|fatigue]] in [[multiple sclerosis]].<ref name="Gabbard2007">{{cite book|author=Glen O. Gabbard|title=Gabbard's Treatments of Psychiatric Disorders|url=https://books.google.com/books?id=-T2aEqfwLW4C&pg=PA174|year=2007|publisher=American Psychiatric Pub|isbn=978-1-58562-216-0|pages=174–}}</ref>

 
With the knowledge of the dopaminergic psychostimulant effects of the adamantane derivatives, bromantane, which is 2-(4-bromophenylamino)adamantane, was developed in the 1980s at the Zakusov State Institute of Pharmacology, [[USSR Academy of Medical Sciences|Russian Academy of Medical Sciences]] in [[Moscow, Russia|Moscow]] as "a drug having psychoactivating and adaptogen properties under complicated conditions (hypoxia, high environmental temperature, physical overfatigue, emotional stress, etc.)".<ref name="OliynykOh2012">{{cite journal|last1=Oliynyk|first1=Sergiy|last2=Oh|first2=Sei-Kwan|title=The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance|journal=Biomolecules & Therapeutics|volume=20|issue=5|year=2012|pages=446–456|issn=1976-9148|doi=10.4062/biomolther.2012.20.5.446}}</ref><ref name="IezhitsaSpasov2001"/> It was found to produce more marked and prolonged psychostimulant effects than the other adamantanes,<ref name="pmid8312546">{{cite journal | vauthors = Krapivin SV, Sergeeva SA, Morozov IS | title = [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane] | language = Russian | journal = Biull Eksp Biol Med | volume = 116 | issue = 11 | pages = 515–8 | year = 1993 | pmid = 8312546 | doi = | url = }}</ref> and eventually entered use.<ref name="OliynykOh2012" /> The drug was notably given to soldiers in the Soviet and Russian militaries to "shorten recovery times after strong physical exertion".<ref name="OliynykOh2012" /> After the break-up of the [[Soviet Union]] in 1991, bromantane continued to be researched and characterized but was mainly limited in use to [[sports medicine]] (for instance, to enhance athletic performance).<ref name="OliynykOh2012" /> In 1996, it was encountered as a [[doping (sport)|doping agent]] in the [[1996 Summer Olympics]] when several Russian athletes tested positive for it, and was subsequently placed on the [[World Anti-Doping Agency]] banned list in 1997 as a stimulant and [[masking agent]].<ref name="OliynykOh2012" /><ref name="BurnatPayen1997">{{cite journal|last1=Burnat|first1=Pascal|last2=Payen|first2=Alain|last3=Brumant-Payen|first3=Catherine Le|last4=Hugon|first4=Michel|last5=Ceppa|first5=Franck|title=Bromontan, a new doping agent|journal=The Lancet|volume=350|issue=9082|year=1997|pages=963–964|issn=0140-6736|doi=10.1016/S0140-6736(05)63310-7|pmid=9314900}}</ref>
